



RECEIVED

JUN 04 2002

Page 1 of 3

Form PTO-1449 (modified)List of Patents and Publications
For Applicant's Information
Disclosure Statement
(Use several sheets if necessary)

ATTY. DOCKET NO: 5333-02600

APPLICANT: Lee et al.

FILING DATE: April 18, 2002

TECH CENTER 1600/2900

SERIAL NO: 10/018,870

GROUP: Unknown

U.S. PATENT DOCUMENTS

EXAM. INITIALS	REF. DES	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
Rb	A1	3,523,906	8/1970	Vrancken et al			
	A2	3,960,757	6/1976	Morishita et al.			
	A3	4,606,940	8/1996	Frank et al.			
	A4	4,652,441	3/1987	Okada et al.			
	A5	4,818,542	4/1989	DeLuca et al.			
	A6	4,962,091	10/1990	Eppstein et al.			
	A7	5,019,400	5/1991	Gombotz et al.			
	A8	5,043,280	8/1991	Fischer et al.			
	A9	5,145,675	9/1992	Won			
	A10	5,160,745	11/1992	DeLuca et al			
	A11	5,271,961	12/1993	Mathiowitz et al			
	A12	5,288,502	2/1994	McGinity et al.			
	A13	5,470,582	11/1995	Supersaxo et al.			
	A14	5,470,682	11/1995	Ashiya et al.			
	A15	5,480,656	1/1996	Okada et al.			
	A16	5,518,709	5/1996	Sutton et al.			
	A17	5,804,557	9/1998	Cleland et al.			
	A18	5,830,493	11/1998	Yokota et al.			
	A19	5,916,597	6/1999	Lee et al.			
	A20	5,942,241	8/1999	Chasin et al.			
	A21	5,942,253	8/1999	Gombotz et al.			

EXAMINER:

Rachel Bennett

DATE CONSIDERED:

10/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent owner.

Information Disclosure Statement--PTO 1449 (modified)



RECEIVED

JUN 04 2002

Page 2 of 3

TECH CENTER 1600/2900

Form PTO-1449 (modified)List of Patents and Publications
For Applicant's Information
Disclosure Statement
(Use several sheets if necessary)

ATTY. DOCKET NO: 5333-02600

APPLICANT: Lee et al.

FILING DATE: April 18, 2002

SERIAL NO: 10/018,970

GROUP: Unknown

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

163	A22	Larger, R., "New methods of drug delivery", Science, 1990, pp 1527-1533.
	A23	in: El-Nokaly, M. A., Piatt, D. M., and Charpentier, B. A. (Eds.), "Polymeric delivery systems, properties and applications", American Chemical Society Symposium Series, 1993, Vol 520 pp. 53-79.
	A24	Park, T. G., "Degradation of poly(lactic-co-glycolic acid) micro,spheres: effect of copolymer composition", Biomaterials, 1995, pp. 1123-1130.
	A25	Anderson et al., "Biodegradation and biocompatibility of PLA and PLGA microspheres", Adv. Drug. Del. Rev., 1997, pp. 5-24.
	A26	Tracy. et al, "Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro", Biomaterials, 1999, pp. 1057-1062.
	A27	McGee et al., "Zero order release of protein from poly(D,L-lactide-co-glycolide) microparticles prepared using a modified phase separation technique", J. Controlled Rel., 1995, pp. 77-86.
	A28	Arrieta et al. "N,N-Dimethylchlorosulfitemethaniminium chloride (SOCL2-DMF) A versatile Dehydrating Reagent. Tetrahedron Letters, 1984, pp. 3365-3368.
	A29	Gander et al.: "Quality improvement of spray-dried, protein-loaded D,L-PLA microspheres by appropriate polymer solvent selection", J. Microencapsul., 1995, pp. 83-97.
	A30	O'Donnell, et al. "Preparation of microspheres by the solvent evaporation technique", Adv. Drug Del. Rel., 1997, pp. 25-42.
	A31	Crotts et al.; "Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues", J. Microencapsul., 1998, pp. 699-713.
	A32	Cleland et al., "The Stability of Recombinant Human Growth Hormone in Poly(lactic-co-glycolic acid) PLGA) Microspheres" Pharm. Res., 1997, pp. 420-425.
	A33	Peanet al., "Why Does PEG 400 Co-Encapsulation Improve NGF Stability and Release from PLGA Biodegradable Microspheres?" Pharm. Res., 1999, pp. 1294-1299.
	A34	Sanchez et al., Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres" Int. J. Pharm., 1999, pp. 255-266.
	A35	Lavelle et al., "The Stability and Immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol", Vaccine, 1999, pp. 516-529.
163	A36	Cleland, J. L. and Jones, A. J. S., "Stable formulations of recombinant human Growth Hormone and interferon- γ for Microencapsulation in Biodegradable Microspheres", Pharm. Research, 1996, pp. 1464-1475.

EXAMINER:

Raechel Bennett

DATE CONSIDERED:

10/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent owner.

Information Disclosure Statement--PTO 1449 (modified)



RECEIVED

JUN 04 2002

Page 3 of 3

TECH CENTER 1600/2900

Form PTO-1449 (modified)
List of Patents and Publications
For Applicant's Information
Disclosure Statement
(Use several sheets if necessary)

ATTY. DOCKET NO: 5333-02600

SERIAL NO: 10/018,970

APPLICANT: Lee et al.

GROUP: Unknown

FILING DATE: April 18, 2002

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	A37	Iwata, M. et al., "Particle size and loading efficiency of poly (D,L-lactic-co-glycolic acid) multiphase microspheres containing water soluble substances prepared by the hydrous and anhydrous solvent evaporation methods", J. Microencapsul., 1999 , pp. 49-58.
	A38	Shishido et al. "Total Syntheses of (+)-Physovenine and (+)-Physostigmine. An Application of Tandem Electrocyclic-[3,3]Sigmatropic Reaction of Benzocyclobutenes", Journal of Organic Chemistry, 1986 , pp. 3007-3011, 5123.
	A39	Glass et al., "(η^5 -C ₅ H ₅)Fe(CO) ₂ (η^1 -C ₃ H ₅). A Useful Synthetic Equivalent of 5-Amino-1,3-cyclopentadiene in Cycloaddition Reactions", Journal of Organic Chemistry, 1986 , pp. 5123-5127
	A40	Kim et al.; "Microencapsulation of Human Growth Hormone within Biodegradable Polyester Microspheres: Protein Aggregation Stability and Incomplete Release Mechanism," Biotechnology and Bioengineering, 1999, pp 659-667.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent owner.

Information Disclosure Statement--PTO 1449 (modified)